Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

Tzu-Rong PengPei-Fei LiaoTa-Wei Wu

Published in: Thoracic cancer (2023)

These results indicated that alectinib could be associated with the best therapeutic efficacy and well-tolerance AEs in the treatment of ALK-positive NSCLC.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
diffuse large b cell lymphoma
combination therapy
replacement therapy
tyrosine kinase